FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W130503066> ?p ?o ?g. }

• W130503066 abstract "High-dose melphalan with autologous stem cell support (SCT) has improved outcomes for patients with systemic AL amyloidosis. A significantly greater proportion of patients remain alive and progression-free 5 or 10 years post-therapy than with historical traditional regimens. However, at most only one-third of newly diagnosed AL patients are eligible for SCT and, as attempts to minimize morbidity and mortality lead to refined patient selection, fewer AL patients may ultimately have SCT made available to them. Standard oral melphalan and dexamethasone, as well as combinations that include the novel agents lenalidomide and bortezomib, may allow for rapid elimination of circulating light chains and achieve response rates similar to SCT. In addition, as more data are obtained about complete response frequency, response duration, and tolerability of the novel agents in AL patients, it is possible that the risk-to-benefit ratio of high-dose therapy as initial treatment will become less favorable and that SCT may become more appropriate as second-line therapy. Indeed, the central challenge of the upcoming decade will be how and when to best incorporate the novel agents, either alone or in combination with both conventional and high-dose chemotherapeutic regimens, into our armamentarium against AL. Certainly, more randomized clinical trials will be needed to answer these questions, requiring cooperative group involvement and cooperation among amyloidosis treatment centers. Fortunately, risk-adapted high-dose therapy and the novel agents have greatly expanded the options for AL patients compared with a decade ago and the future continues to look bright." @default.
• W130503066 created "2016-06-24" @default.
• W130503066 creator A5025168585 @default.
• W130503066 creator A5033672095 @default.
• W130503066 date "2010-01-01" @default.
• W130503066 modified "2023-09-26" @default.
• W130503066 title "High-Dose Therapy in Amyloidosis" @default.
• W130503066 cites W1891153794 @default.
• W130503066 cites W1903976067 @default.
• W130503066 cites W1971828262 @default.
• W130503066 cites W1972660255 @default.
• W130503066 cites W1973423645 @default.
• W130503066 cites W1994394328 @default.
• W130503066 cites W1995859732 @default.
• W130503066 cites W2001594121 @default.
• W130503066 cites W2007712573 @default.
• W130503066 cites W2011865037 @default.
• W130503066 cites W2012879531 @default.
• W130503066 cites W2024799625 @default.
• W130503066 cites W2026295989 @default.
• W130503066 cites W2027659061 @default.
• W130503066 cites W2028114340 @default.
• W130503066 cites W2031571078 @default.
• W130503066 cites W2032378618 @default.
• W130503066 cites W2033793452 @default.
• W130503066 cites W2034080653 @default.
• W130503066 cites W2036282307 @default.
• W130503066 cites W2036497786 @default.
• W130503066 cites W2039150089 @default.
• W130503066 cites W2039282816 @default.
• W130503066 cites W2039607042 @default.
• W130503066 cites W2040582241 @default.
• W130503066 cites W2041167176 @default.
• W130503066 cites W2042839483 @default.
• W130503066 cites W2053103108 @default.
• W130503066 cites W2056797282 @default.
• W130503066 cites W206392377 @default.
• W130503066 cites W2069078219 @default.
• W130503066 cites W2073764721 @default.
• W130503066 cites W2080214236 @default.
• W130503066 cites W2081068834 @default.
• W130503066 cites W2084582635 @default.
• W130503066 cites W2085845045 @default.
• W130503066 cites W2089163478 @default.
• W130503066 cites W2092074428 @default.
• W130503066 cites W2098093182 @default.
• W130503066 cites W2098327097 @default.
• W130503066 cites W2102591890 @default.
• W130503066 cites W2106512137 @default.
• W130503066 cites W2107104642 @default.
• W130503066 cites W2107403553 @default.
• W130503066 cites W2109651910 @default.
• W130503066 cites W2113366568 @default.
• W130503066 cites W2118848299 @default.
• W130503066 cites W2126000176 @default.
• W130503066 cites W2127143739 @default.
• W130503066 cites W2135482314 @default.
• W130503066 cites W2141145512 @default.
• W130503066 cites W2144506100 @default.
• W130503066 cites W2158206316 @default.
• W130503066 cites W2168613652 @default.
• W130503066 cites W2169767242 @default.
• W130503066 cites W2316718219 @default.
• W130503066 cites W2332241363 @default.
• W130503066 cites W2412985261 @default.
• W130503066 cites W3009298687 @default.
• W130503066 cites W4230680279 @default.
• W130503066 cites W4238487952 @default.
• W130503066 cites W4255800108 @default.
• W130503066 cites W86094332 @default.
• W130503066 cites W2333363976 @default.
• W130503066 doi "https://doi.org/10.1007/978-1-60761-631-3_12" @default.
• W130503066 hasPublicationYear "2010" @default.
• W130503066 type Work @default.
• W130503066 sameAs 130503066 @default.
• W130503066 citedByCount "0" @default.
• W130503066 crossrefType "book-chapter" @default.
• W130503066 hasAuthorship W130503066A5025168585 @default.
• W130503066 hasAuthorship W130503066A5033672095 @default.
• W130503066 hasConcept C126322002 @default.
• W130503066 hasConcept C141071460 @default.
• W130503066 hasConcept C143998085 @default.
• W130503066 hasConcept C159654299 @default.
• W130503066 hasConcept C177713679 @default.
• W130503066 hasConcept C197934379 @default.
• W130503066 hasConcept C203014093 @default.
• W130503066 hasConcept C2776063141 @default.
• W130503066 hasConcept C2776364478 @default.
• W130503066 hasConcept C2777478702 @default.
• W130503066 hasConcept C2778375690 @default.
• W130503066 hasConcept C2778684742 @default.
• W130503066 hasConcept C2779551797 @default.
• W130503066 hasConcept C2779951007 @default.
• W130503066 hasConcept C2780401358 @default.
• W130503066 hasConcept C36394416 @default.
• W130503066 hasConcept C535046627 @default.
• W130503066 hasConcept C71924100 @default.
• W130503066 hasConceptScore W130503066C126322002 @default.
• W130503066 hasConceptScore W130503066C141071460 @default.
• W130503066 hasConceptScore W130503066C143998085 @default.

• next